Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

June 20, 2024

https://www.prnewswire.com/news-releases/coeptis-therapeutics-closes-on-4-3-million-of-series-a-preferred-offering-302177491.html

Bolsters Company’s Corporate Mission

Financing Led by Board Member and Priced at Premium to Market Price

WEXFORD, Pa., June 20, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.